Phase 2 Study of Atorvastatin Safety and Antitumor Effects in Non-Hodgkin's Lymphoma
Status:
Completed
Trial end date:
2012-11-01
Target enrollment:
Participant gender:
Summary
This is an approach which can inflict significant toxicity. An alternative is to block
expression of oncogenes which are over-expressed only in cancer cells, a therapeutic approach
which could reduce toxicity to the host while maximizing destruction of the
oncogene-dependent malignant cells.
Phase:
Phase 2
Details
Lead Sponsor:
Dean Felsher
Collaborators:
Burroughs Wellcome Damon Runyon Cancer Research Foundation The Leukemia and Lymphoma Society